Celgene buys stake in Mesoblast
This article was originally published in Scrip
Celgene has agreed to buy a minority stake in Australian regenerative therapy firm Mesoblast, shelling out Aus$58.5m (US$45m) for 15.3 million shares, or around 4.8% of outstanding stock. The deal values Mesoblast's stock at Aus$3.82 per share, a 19% premium over its closing price of Aus$3.21 on 10 April, the last trading day before the transaction was announced. The firm's share price closed up 24% at Aus$3.99 on 13 April.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.